November 7 - 9, 2019 | Baltimore Convention Center
The AMP Annual Meeting has truly become pathology’s global event. Decision makers in the field of pathology and the related specialties of molecular, toxicology, oncology, and immunology from hospitals, private laboratories, academic institutions, and the government will be in attendance. We are continually setting records for attendance and the number of exhibitors over the past several years and look forward to doing the same in 2019.
November 7 - 9, 2019
Baltimore Convention Center
Booth #2840
VISIT US AT AMP 2019 IN BALTIMORE!
Join our corporate workshop on Wednesday, November 6! Learn more about Biocartis’ fully-automated oncology biomarker testing platform from three experienced Idylla™ users:
High sensitivity mutation analysis in pleural and pancreatic fluids
Dr. Maria Arcila,
Memorial Sloan Kettering Cancer Center
A multicenter study of improved TAT for somatic mutation analysis
Dr. Gregory J. Tsongalis,
Dartmouth-Hitchcock Medical Center
Implementation and cost benefit analysis of the fully automated Idylla™ system in a large laboratory setting
Dr. Yi Ding,
Geisinger Medical Laboratories
YOU ARE ABOUT TO EXIT FOR ANOTHER BIOCARTIS COUNTRY OR REGION SPECIFIC WEBSITE
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
DO YOU WISH TO CONTINUE AND EXIT THIS SITE?
DISCLAIMER:
This information concerns a use that has not been approved or cleared by the Food and Drug Administration.
Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.
DISCLAIMER:
This presentation is intellectual property of the individual presenters. The opinions and conclusions expressed in these presentations are those of the individual presenters and do not necessarily reflect the views and opinions of Biocartis and/or its employees.
One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.
